Botulinum AntiToxin

Phase 3Small molecule

DDepartment of Medical Services Ministry of Public Health of Thailand

Botulinum AntiToxin is one of 14 small molecule programs targeting Migraine Without Aura. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Migraine Without AuraActive, not recruiting

Migraine Without AuraPhase 3

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Migraine Without Aura

#DrugCompanyPhaseTrials

Rozerem

Takeda

Approved

—2

Marinol

Alnylam Pharmaceuticals

Approved

—3

Inderal

WWyeth-Lederle Vaccines

Approved

—4

Vivarin

HHikma Pharmaceuticals LLC

Atacand

Botulinum AntiToxin

DDepartment of Medical Services Ministry of Public Health of Thailand

Phase 3

1 7

Corlanor

Amgen

Preclinical

1 8

Vyepti

Lundbeck

Preclinical

1 9

Adempas

Bayer

Preclinical

—10

Viagra

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Botulinum AntiToxin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Botulinum AntiToxin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Botulinum AntiToxin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Department of Medical Services Ministry of Public Health of Thailand company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDepartment of Medical Services Ministry of Public Health of Thailand

Botulinum AntiToxin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Migraine Without Aura1 trial

Treatment1 trial

Botulism1 trial

References

Drug Info

Quick Facts

Related News